Across TCGA pan-cancer cohorts, NETO1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NETO1 data layer compared with 23 for mass-spec protein and 9 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher NETO1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NETO1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM are the cancer types where NETO1 mass-spec protein most reproducibly stratifies survival.